[go: up one dir, main page]

RU2017125758A - Антитела к с5 и способы их применения - Google Patents

Антитела к с5 и способы их применения Download PDF

Info

Publication number
RU2017125758A
RU2017125758A RU2017125758A RU2017125758A RU2017125758A RU 2017125758 A RU2017125758 A RU 2017125758A RU 2017125758 A RU2017125758 A RU 2017125758A RU 2017125758 A RU2017125758 A RU 2017125758A RU 2017125758 A RU2017125758 A RU 2017125758A
Authority
RU
Russia
Prior art keywords
seq
antibody
amino acid
paragraphs
antibody according
Prior art date
Application number
RU2017125758A
Other languages
English (en)
Other versions
RU2017125758A3 (ru
RU2746356C2 (ru
Inventor
Ёсинао Руике
Дзендзиро Сампей
Original Assignee
Чугаи Сейяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугаи Сейяку Кабусики Кайся filed Critical Чугаи Сейяку Кабусики Кайся
Publication of RU2017125758A publication Critical patent/RU2017125758A/ru
Publication of RU2017125758A3 publication Critical patent/RU2017125758A3/ru
Application granted granted Critical
Publication of RU2746356C2 publication Critical patent/RU2746356C2/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)

Claims (45)

1. Выделенное антитело, которое связывается с С5, где антитело связывается с эпитопом в бета-цепи С5 с более высокой аффинностью при нейтральном рН, чем при кислом рН.
2. Антитело по п. 1, где антитело обладает характеристикой, выбранное из группы, которая состоит из следующих характеристик:
(а) антитело контактирует с аминокислотами D51 и K109 С5 (SEQ ID NO: 39);
(б) аффинность антитела к С5 (SEQ ID NO: 39) больше, чем аффинность антитела к мутант С5, содержащему замену Е48А в SEQ ID NO: 39; и
(в) антитело связывается с белком С5, состоящим из аминокислотной последовательности SEQ ID NO: 39, при рН 7,4, но не связывается с белком С5, состоящим из аминокислотной последовательности SEQ ID NO: 39 с заменой H72Y, при рН 7,4.
3. Антитело по п. 1, где антитело конкурирует за связывание с С5 с антителом, которое содержит пару VH и VL, выбранную из:
(а) VH, имеющей SEQ ID NO: 1, и VL, имеющей SEQ ID NO: 11;
(б) VH, имеющей SEQ ID NO: 5, и VL, имеющей SEQ ID NO: 15;
(в) VH, имеющей SEQ ID NO: 4, и VL, имеющей SEQ ID NO: 14;
(г) VH, имеющей SEQ ID NO: 6, и VL, имеющей SEQ ID NO: 16;
(д) VH, имеющей SEQ ID NO: 2, и VL, имеющей SEQ ID NO: 12;
(е) VH, имеющей SEQ ID NO: 3, и VL, имеющей SEQ ID NO: 13;
(ж) VH, имеющей SEQ ID NO: 9, и VL, имеющей SEQ ID NO: 19;
(з) VH, имеющей SEQ ID NO: 7, и VL, имеющей SEQ ID NO: 17;
(и) VH, имеющей SEQ ID NO: 8, и VL, имеющей SEQ ID NO: 18, и
(к) VH, имеющей SEQ ID NO: 10, и VL, имеющей SEQ ID NO: 20.
4. Антитело по одному из пп. 1-3, где антитело связывается с эпитопом в домене MG1-MG2 бета-цепи С5.
5. Антитело по одному из пп. 1-4, где антитело связывается с эпитопом во фрагменте, состоящем из аминокислот 33-124 бета-цепи (SEQ ID NO: 40) С5.
6. Антитело по одному из пп. 1-5, где антитело связывается с эпитопом в бета-цепи (SEQ ID NO: 40) С5, который содержит по меньшей мере один фрагмент выбранный из группы, которая состоит из аминокислот 47-57, 70-76 и 107-110.
7. Антитело по одному из пп. 1-6, где антитело связывается с эпитопом во фрагменте бета-цепи (SEQ ID NO: 40) С5, который содержит по меньшей мере одну аминокислоту, выбранную из группы, которая состоит из Glu48, Asp51, His70, His72, Lys109 и His110.
8. Антитело по одному из пп. 1-7, которое связывается с тем же эпитопом, что и антитело, описанное в таблицах 2, 7 или 8.
9. Антитело по одному из пп. 1-8, которое ингибирует активацию С5.
10. Антитело по одному из пп. 1-9, которое ингибирует активацию R885H-варианта С5.
11. Антитело по одному из пп. 1-10, которое представляет собой моноклональное антитело.
12. Антитело по одному из пп. 1-11, которое представляет собой человеческое, гуманизированное или химерное антитело.
13. Антитело по одному из пп. 1-12, которое представляет собой фрагмент антитела, который связывается с С5.
14. Антитело по одному из пп. 1-13, где антитело содержит (a) HVR-H3, включающий аминокислотную последовательность DX1GYX2X3PTHAMX4X5, в которой X1 обозначает G или А, Х2 обозначает V, Q или D, Х3 обозначает Т или Y, X4 обозначает Y или H, X5 обозначает L или Y (SEQ ID NO: 128), (б) a HVR-L3, включающий аминокислотную последовательность QX1TX2VGSSYGNX3, в которой X1 обозначает S, С, N или Т, Х2 обозначает F или K, Х3 обозначает А, Т или Н (SEQ ID NO: 131), и (в) HVR-H2, включающий аминокислотную последовательность X1IX2TGSGAX3YX4AX5WX6KG, в которой X1 обозначает С, А или G, Х2 обозначает Y или F, Х3 обозначает Т, D или Е, Х4 обозначает Y, K или Q, Х5 обозначает S, D или Е, Х6 обозначает А или V (SEQ ID NO: 127).
15. Антитело по одному из пп. 1-13, где антитело содержит (a) HVR-H1, включающий аминокислотную последовательность SSYYX1X2, в которой X1 обозначает М или V, Х2 обозначает С или A (SEQ ID NO: 126), (б) HVR-H2, включающий аминокислотную последовательность X1IX2TGSGAX3YX4AX5WX6KG, в которой X1 обозначает С, А или G, Х2 обозначает Y или F, Х3 обозначает Т, D или Е, Х4 обозначает Y, K или Q, Х5 обозначает S, D или Е, Х6 обозначает А или V (SEQ ID NO: 127), и (в) HVR-H3, включающий аминокислотную последовательность DX1GYX2X3PTHAMX4X5, в которой X1 обозначает G или А, Х2 обозначает V, Q или D, Х3 обозначает Т или Y, Х4 обозначает Y или Н, Х5 обозначает L или Y (SEQ ID NO: 128).
16. Антитело по п. 15, которое дополнительно содержит (a) HVR-L1, включающий аминокислотную последовательность X1ASQX2IX3SX4LA, в которой X1 обозначает Q или R, Х2 обозначает N, Q или G, Х3 обозначает G или S, Х4 обозначает D, K или S (SEQ ID NO: 129); (б) HVR-L2, включающий аминокислотную последовательность GASX1X2X3S, в которой X1 обозначает K, Е или Т, Х2 обозначает L или Т, Х3 обозначает А, Н, Е или Q (SEQ ID NO: 130); и (в) HVR-L3, включающий аминокислотную последовательность QX1TX2VGSSYGNX3, в которой X1 обозначает S, С, N или Т, Х2 обозначает F или K, Х3 обозначает А, Т или Н (SEQ ID NO: 131).
17. Антитело по одному из пп. 1-13, которое содержит (a) HVR-L1, включающий аминокислотную последовательность X1ASQX2IX3SX4LA, в которой X1 обозначает Q или R, Х2 обозначает N, Q или G, Х3 обозначает G или S, Х4 обозначает D, K или S (SEQ ID NO: 129); (б) HVR-L2, включающий аминокислотную последовательность GASX1X2X3S, в которой X1 обозначает K, Е или Т, Х2 обозначает L или Т, Х3 обозначает А, Н, Е или Q (SEQ ID NO: 130); и (в) HVR-L3, включающий аминокислотную последовательность QX1TX2VGSSYGNX3, в которой X1 обозначает S, С, N или Т, Х2 обозначает F или K, Х3 обозначает А, Т или Н (SEQ ID NO: 131).
18. Антитело по п. 15, которое дополнительно содержит каркасный участок вариабельного домена тяжелой цепи FR1, включающий одну из аминокислотных последовательностей SEQ ID NO: 132-134; FR2, включающий одну из аминокислотных последовательностей SEQ ID NO: 135-136; и FR3, включающий одну из аминокислотных последовательностей SEQ ID NO: 137-139; и FR4, включающий одну из аминокислотных последовательностей SEQ ID NO: 140-141.
19. Антитело по п. 17, которое дополнительно содержит каркасный участок вариабельного домена легкой цепи FR1, включающий одну из аминокислотных последовательностей SEQ ID NO: 142-143; FR2, включающий одну из аминокислотных последовательностей SEQ ID NO: 144-145; FR3, включающий одну из аминокислотных последовательностей SEQ ID NO: 146-147; и FR4, включающий аминокислотную последовательность SEQ ID NO: 148.
20. Антитело по одному из пп. 1-13, которое содержит (а) последовательность VH, идентичную по меньшей мере на 95% одной из аминокислотных последовательностей SEQ ID NO: 10, 106-110; (б) последовательность VL, идентичную по меньшей мере на 95% одной из аминокислотных последовательностей SEQ ID NO: 20, 111-113; или (в) последовательность VH, указанную в подпункте (а), и последовательность VL, указанную в подпункте (б).
21. Антитело по п. 20, содержащее последовательность VH, представленную в одной из SEQ ID NO: 10, 106-110.
22. Антитело по п. 20, содержащее последовательность VL, представленную в одной из SEQ ID NO: 20, 111-113.
23. Антитело, содержащее последовательность VH, представленную в одной из SEQ ID NO: 10, 106-110, и последовательность VL, представленную в одной из SEQ ID NO: 20, 111-113.
24. Антитело по одному из пп. 1-23, которое представляет собой полноразмерное антитело IgG1-класса или IgG4-класса.
25. Выделенная нуклеиновая кислота, кодирующая антитело по одному из пп. 1-24.
26. Клетка-хозяин, содержащая нуклеиновую кислоту по п. 25.
27. Способ получения антитела, включающий культивирование клетки-хозяина по п. 26, в результате чего получают антитело.
28. Способ получения антитела к С5, включающий иммунизацию животного полипептидом, где полипептид содержит домен MG1-MG2 (SEQ ID NO: 43) бета-цепи С5.
29. Способ получения антитела к С5, включающий иммунизацию животного полипептидом, где полипептид содержит область, соответствующую аминокислотам в положениях 33-124 бета-цепи (SEQ ID NO: 40) С5.
30. Способ получения антитела к С5, включающий иммунизацию животного полипептидом, где полипептид содержит по меньшей мере один фрагмент, выбранный из аминокислот 47-57, 70-76 и 107-110 бета-цепи (SEQ ID NO: 40) С5.
31. Способ получения антитела к С5, включающий иммунизацию животного полипептидом, где полипептид содержит фрагмент бета-цепи (SEQ ID NO: 40) С5, который содержит по меньшей мере одну аминокислоту, выбранную из Glu48, Asp51, His70, His72, Lys109 и His110.
32. Фармацевтическая композиция, содержащая антитело по одному из пп. 1-24 и фармацевтически приемлемый носитель.
RU2017125758A 2014-12-19 2015-12-18 Антитела к с5 и способы их применения RU2746356C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014257647 2014-12-19
JP2014-257647 2014-12-19
PCT/JP2015/006321 WO2016098356A1 (en) 2014-12-19 2015-12-18 Anti-c5 antibodies and methods of use

Publications (3)

Publication Number Publication Date
RU2017125758A true RU2017125758A (ru) 2019-01-22
RU2017125758A3 RU2017125758A3 (ru) 2019-10-25
RU2746356C2 RU2746356C2 (ru) 2021-04-12

Family

ID=56126263

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017125758A RU2746356C2 (ru) 2014-12-19 2015-12-18 Антитела к с5 и способы их применения

Country Status (30)

Country Link
US (5) US9765135B2 (ru)
EP (2) EP3981794A1 (ru)
JP (2) JP6174782B2 (ru)
KR (3) KR102515796B1 (ru)
CN (2) CN113045650A (ru)
AR (1) AR103162A1 (ru)
AU (1) AU2015365167B2 (ru)
BR (1) BR112017011235A2 (ru)
CA (1) CA2967554A1 (ru)
CL (2) CL2017001585A1 (ru)
CO (1) CO2017006651A2 (ru)
CR (1) CR20170251A (ru)
EA (1) EA201791366A1 (ru)
ES (1) ES2899894T3 (ru)
HR (1) HRP20211934T1 (ru)
HU (1) HUE056489T2 (ru)
LT (1) LT3233921T (ru)
MX (1) MX384138B (ru)
MY (1) MY183415A (ru)
PH (1) PH12017501114B1 (ru)
PL (1) PL3233921T3 (ru)
PT (1) PT3233921T (ru)
RS (1) RS62749B1 (ru)
RU (1) RU2746356C2 (ru)
SG (2) SG11201607165YA (ru)
SI (1) SI3233921T1 (ru)
TW (3) TWI617580B (ru)
UA (1) UA128712C2 (ru)
WO (1) WO2016098356A1 (ru)
ZA (1) ZA201703241B (ru)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2752200B1 (en) 2011-09-30 2023-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP4624490A3 (en) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
US20150166654A1 (en) 2012-05-30 2015-06-18 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
WO2014030728A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 FcγRIIb特異的Fc領域改変体
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
IL259256B2 (en) * 2015-12-18 2023-02-01 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
EP3402816A1 (en) 2016-01-11 2018-11-21 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
CN114703244A (zh) 2016-05-10 2022-07-05 豪夫迈·罗氏有限公司 重组产生多肽期间减少三硫键的方法
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
LT3468990T (lt) 2016-06-14 2024-06-25 Regeneron Pharmaceuticals, Inc. Anti-c5 antikūnai ir jų panaudojimas
TWI807666B (zh) * 2016-06-17 2023-07-01 日商中外製藥股份有限公司 抗c5抗體及使用方法
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018044858A2 (en) * 2016-08-29 2018-03-08 The Cleveland Clinic Foundation C5 immunization for autologous anti-c5 antibody production
CN110087683A (zh) * 2016-12-16 2019-08-02 三星Bioepis股份有限公司 稳定水性抗c5抗体组合物
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
WO2018143266A1 (en) * 2017-01-31 2018-08-09 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CN110603054B (zh) * 2017-03-06 2024-05-10 宾夕法尼亚大学理事会 抗c5抗体及其用途
WO2018217638A1 (en) 2017-05-22 2018-11-29 Alexion Pharmaceuticals Inc. Dosage and administration of anti-c5 antibodies for treatment of protein-losing enteropathy in patients
CN116271012A (zh) 2017-07-27 2023-06-23 瑞颂医药公司 高浓度抗c5抗体制剂
BR112020008182A2 (pt) 2017-10-26 2020-10-27 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
EP4640703A2 (en) * 2017-11-14 2025-10-29 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
JP2021519073A (ja) 2018-03-29 2021-08-10 ジェネンテック， インコーポレイテッド 哺乳動物細胞におけるラクトジェニック活性の制御
EP3803407A1 (en) * 2018-05-24 2021-04-14 Sigma-Aldrich Co. LLC Quantitative analysis of proteins
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体の産生方法
CA3107618A1 (en) * 2018-08-01 2020-02-06 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2021002710A (es) * 2018-09-06 2021-09-23 Univ Pennsylvania Anticuerpos anti-c5 humanizados y usos de los mismos.
EP3852874A1 (en) * 2018-09-17 2021-07-28 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
EP3852876A1 (en) 2018-09-21 2021-07-28 Alexion Pharmaceuticals, Inc. Eculuzimab for the treatment of neuromyelitis opticae
US20210388070A1 (en) * 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
WO2020092549A1 (en) 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
ES2980453T3 (es) 2019-01-25 2024-10-01 Alexion Pharma Inc Dosificación y administración de anticuerpos anti-c5 para el tratamiento del síndrome urémico hemolítico atípico (ahus)
CN119326881A (zh) 2019-02-14 2025-01-21 亚力兄制药公司 抗c5抗体用于治疗全身型重症肌无力的剂量和施用
WO2020213706A1 (en) * 2019-04-19 2020-10-22 Chugai Seiyaku Kabushiki Kaisha Antibodies and compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample
AU2020257748A1 (en) 2019-04-19 2021-11-18 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor recognizing modification site of antibody
KR20220016865A9 (ko) 2019-05-15 2022-02-21 추가이 세이야쿠 가부시키가이샤 항원 결합 분자, 약학 조성물, 및 방법
US20220227851A1 (en) 2019-05-24 2022-07-21 Alexion Pharmaceuticals, Inc. Methods of treating vitiligo using an anti-c5 antibody
KR20240033090A (ko) 2019-07-31 2024-03-12 에프. 호프만-라 로슈 아게 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
AU2020319677A1 (en) 2019-07-31 2022-01-06 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab
US20220356234A1 (en) 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
US20230043034A1 (en) 2019-12-09 2023-02-09 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
JP7734673B2 (ja) 2019-12-23 2025-09-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
CA3169908A1 (en) 2020-03-26 2021-09-30 Genentech, Inc. Modified mammalian cells having reduced host cell proteins
KR20220161375A (ko) 2020-03-31 2022-12-06 추가이 세이야쿠 가부시키가이샤 다중 특이성 항원 결합 분자를 제조하기 위한 방법
CN113563467A (zh) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 针对人补体蛋白c5的抗体及其应用
WO2021231470A1 (en) 2020-05-12 2021-11-18 Alexion Pharmaceuticals, Inc. Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria
WO2021231720A1 (en) 2020-05-15 2021-11-18 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
AU2021281445A1 (en) * 2020-05-29 2022-12-22 Amgen Inc. Antibody formulations and uses thereof
MX2022016453A (es) 2020-06-24 2023-02-01 Genentech Inc Lineas celulares resistentes a la apoptosis.
WO2021262329A1 (en) 2020-06-24 2021-12-30 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions
CN114364695B (zh) * 2020-06-24 2024-07-12 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用
JP2023533030A (ja) 2020-07-09 2023-08-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者において発作性夜間血色素尿症（ｐｎｈ）を治療するための抗ｃ５抗体の投薬量及び投与
MX2023001702A (es) 2020-08-13 2023-03-09 Alexion Pharma Inc Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma).
JP2023539201A (ja) 2020-08-28 2023-09-13 ジェネンテック， インコーポレイテッド 宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
KR20230073261A (ko) 2020-09-21 2023-05-25 알렉시온 파마슈티칼스, 인코포레이티드 루푸스 신장염(ln) 및/또는 iga 신장병(igan)을 포함하는, c5-매개 사구체 신장염(gn)을 치료하기 위한 항-c5 항체의 투여량 및 투여
WO2022087339A1 (en) 2020-10-23 2022-04-28 Alexion Pharmaceuticals, Inc. Methods of treating patients having complement disorders using anti-c5 antibodies
EP4378479A3 (en) 2021-01-22 2024-09-25 Alexion Pharmaceuticals, Inc. Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
TW202305122A (zh) 2021-04-19 2023-02-01 美商建南德克公司 經修飾之哺乳動物細胞
EP4341385A1 (en) 2021-05-21 2024-03-27 Genentech, Inc. Modified cells for the production of a recombinant product of interest
TW202306994A (zh) 2021-06-04 2023-02-16 日商中外製藥股份有限公司 抗ddr2抗體及其用途
WO2022265915A1 (en) 2021-06-14 2022-12-22 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm)
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
CR20240026A (es) * 2021-06-25 2024-03-14 Chugai Pharmaceutical Co Ltd Anticuerpo anti-ctla-4
US20250154232A1 (en) 2021-07-14 2025-05-15 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
TW202404632A (zh) 2022-04-04 2024-02-01 瑞士商赫孚孟拉羅股份公司 用於藉由使用抗ｃ５抗體克羅伐單抗治療或預防格林－巴利症候群之劑量及投予方案
TW202346339A (zh) 2022-04-04 2023-12-01 瑞士商赫孚孟拉羅股份公司 藉由使用抗ｃ５抗體克羅伐單抗之治療或預防格林－巴利症候群之劑量及投予方案
CA3251727A1 (en) * 2022-05-04 2023-11-09 Alexion Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISORDER ON THE SPECTRUM OF OPTICAL NEUROMYELITIS
CA3266977A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)
TW202426048A (zh) 2022-09-06 2024-07-01 美商阿雷希昂製藥公司 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與
TW202423479A (zh) 2022-09-28 2024-06-16 美商阿雷希昂製藥公司 用於預防或最小化患有慢性腎病的患者中的心臟手術相關急性腎損傷（csa-aki）和/或隨後的主要不良腎事件（make）的抗c5抗體之劑量及投與
WO2024238421A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of biomarkers for the identification and treatment of complement-mediated disorders
WO2024238422A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
WO2025006898A1 (en) * 2023-06-29 2025-01-02 Beam Therapeutics Inc. Anti-idiotypic antibodies to cluster of differentiation 7-targeted binding domains and related compositions and methods
WO2025045251A2 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Multispecific constructs comprising anti-factor d moiety
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025166118A1 (en) 2024-02-02 2025-08-07 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan)
WO2025221479A1 (en) 2024-04-16 2025-10-23 Alexion Pharmaceuticals, Inc. Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors

Family Cites Families (276)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5144499B1 (ru) 1970-08-29 1976-11-29
JPS5824836B2 (ja) 1974-10-14 1983-05-24 ノウミボウサイコウギヨウ カブシキガイシヤ カサイナドノツウホウソウチ
US4769320A (en) 1982-07-27 1988-09-06 New England Medical Center Hospitals, Inc. Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations
CA1209907A (en) 1982-04-12 1986-08-19 Richard M. Bartholomew Method of affinity purification employing monoclonal antibodies
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
JPS6350741A (ja) 1986-08-20 1988-03-03 Nippon Tectron Co Ltd 蛍光偏光分析装置
JPH06104071B2 (ja) 1986-08-24 1994-12-21 財団法人化学及血清療法研究所 第▲ｉｘ▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2006684C (en) 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
US5202253A (en) 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
JPH0636741B2 (ja) 1989-11-08 1994-05-18 帝人株式会社 ヒト・プロテインｃの分離方法
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69130561T2 (de) 1990-02-16 1999-06-24 Boston Biomedical Research Institute, Inc., Boston, Mass. Hybride Reagenzien mit der Fähigkeit, Moleküle selektiv in Zellen freizusetzen
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
ATE322547T1 (de) 1993-06-10 2006-04-15 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
EP0783893B1 (en) 1994-10-07 2012-04-04 Chugai Seiyaku Kabushiki Kaisha Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient
DE4436561C1 (de) 1994-10-13 1996-03-14 Deutsche Spezialglas Ag Verfahren zur Veränderung der Durchbiegung von anodisch gebondeten flächigen Verbundkörpern aus Glas und Metall oder Halbleitermaterialien
CA2203182C (en) 1994-10-21 2009-11-24 Asao Katsume Remedy for diseases caused by il-6 production
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5830478A (en) 1995-06-07 1998-11-03 Boston Biomedical Research Institute Method for delivering functional domains of diphtheria toxin to a cellular target
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6211150B1 (en) 1996-07-19 2001-04-03 Amgen Inc. Analogs of cationic proteins
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
DE69807679T2 (de) 1997-04-17 2003-07-31 Amgen Inc., Thousand Oaks Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE373712T1 (de) 1997-10-03 2007-10-15 Chugai Pharmaceutical Co Ltd Natürlicher menschlicher antikörper
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE512225T1 (de) 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1222292B1 (en) 1999-10-04 2005-08-31 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
DK1242438T3 (da) 1999-12-29 2007-02-12 Immunogen Inc Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
WO2001082899A2 (en) 2000-05-03 2001-11-08 Mbt Munich Biotechnology Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
KR20060088905A (ko) 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
WO2002030985A2 (en) 2000-10-10 2002-04-18 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
NZ529494A (en) 2001-04-13 2005-08-26 Biogen Idec Inc Antibodies to VLA-1
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
CA2451493C (en) 2001-06-22 2016-08-23 Chugai Seiyaku Kabushiki Kaisha Cell growth inhibitors containing anti-glypican 3 antibody
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002331601B2 (en) 2001-08-17 2006-04-13 Tanox, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
CN100374457C (zh) 2001-11-14 2008-03-12 森托科尔公司 抗il-6抗体、组合物、方法和用途
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US6684637B2 (en) 2002-01-25 2004-02-03 Sunpower, Inc. Parallel slot heat exchanger
BR0307548A (pt) 2002-02-11 2006-01-17 Genentech Inc Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
MXPA04009924A (es) 2002-04-09 2005-07-01 Kyowa Hakko Kogyo Kk Celulas de genoma modificado.
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
AU2003248652A1 (en) 2002-06-12 2003-12-31 Genencor International, Inc. Methods for improving a binding characteristic of a molecule
US20060141456A1 (en) 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
JP2005535341A (ja) 2002-08-15 2005-11-24 エピトミスク インコーポレーティッド ヒト化ウサギ抗体
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AR042485A1 (es) 2002-12-16 2005-06-22 Genentech Inc Anticuerpo humanizado que se une al cd20 humano
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
JP2006517109A (ja) 2003-02-07 2006-07-20 プロテイン デザイン ラブス インコーポレイテッド アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
AU2004268497A1 (en) 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
DK1601697T3 (da) 2003-02-28 2007-10-01 Lonza Biologics Plc Oprensning af antistof ved protein A- og ionbytningskromatografi
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
NZ543712A (en) 2003-06-05 2008-06-30 Genentech Inc Combination therapy for B cell disorders
CA2534959A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
US7820800B2 (en) 2003-11-05 2010-10-26 Ares Trading S.A. Process for the purification of IL-18 binding protein
CN104998273A (zh) 2003-11-06 2015-10-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
KR101151477B1 (ko) 2003-12-10 2012-06-22 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
NZ548702A (en) 2004-01-09 2009-06-26 Pfizer Antibodies to MAdCAM
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
ES2341461T5 (es) 2004-02-11 2014-10-29 Warner-Lambert Company Llc Procedimientos de tratamiento de la artrosis con anticuerpos ANTI-IL-6
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
WO2005112564A2 (en) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Germline and sequence variants of humanized antibodies and methods of making and using them
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Ｔａｇ-72에 대한 인간화 항체
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
KR20070034512A (ko) 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US20060019342A1 (en) 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
DK2471813T3 (en) 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
DK2213683T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
MX2007002883A (es) 2004-09-13 2007-06-15 Macrogenics Inc Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
US20080233131A1 (en) 2004-09-14 2008-09-25 Richard John Stebbings Vaccine
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
ATE461211T1 (de) 2004-12-23 2010-04-15 Novo Nordisk As Liganden mit antikörperbindender affinität
GB0502358D0 (en) 2005-02-04 2005-03-16 Novartis Ag Organic compounds
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
EP2824183B1 (en) 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing bispecific antibodies
EP1885755A4 (en) 2005-05-05 2009-07-29 Univ Duke CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
SI1915397T1 (sl) 2005-08-19 2015-05-29 Wyeth Llc Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
ES2551604T3 (es) * 2005-12-12 2015-11-20 Ac Immune S.A. Vacuna terapéutica
PT2548577T (pt) 2005-12-29 2017-05-29 Janssen Biotech Inc Anticorpos humanos anti-il-23, composições, métodos e usos
EP2918269A1 (en) 2006-03-02 2015-09-16 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
AU2007223796B2 (en) 2006-03-08 2013-01-24 Astellas Us Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
WO2007106585A1 (en) 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
NZ611859A (en) 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
PT2047863E (pt) 2006-06-08 2013-10-21 Chugai Pharmaceutical Co Ltd Prevenção ou tratamento para doença inflamatória
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
CA2665287C (en) 2006-10-06 2022-08-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
AU2008228247A1 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP3543691A1 (en) 2007-06-29 2019-09-25 Quest Diagnostics Investments Incorporated Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
AU2008304756B8 (en) 2007-09-26 2015-02-12 Chugai Seiyaku Kabushiki Kaisha Anti-IL-6 receptor antibody
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2620448A1 (en) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin antibodies and methods of use
CA2726934C (en) 2008-06-14 2018-04-24 Vytronus, Inc. System and method for delivering energy to tissue
BRPI0916668B1 (pt) 2008-08-05 2021-12-28 Novartis Ag Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CN109045296A (zh) 2008-11-10 2018-12-21 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
US20100292443A1 (en) 2009-02-26 2010-11-18 Sabbadini Roger A Humanized platelet activating factor antibody design using anti-lipid antibody templates
KR20120105405A (ko) 2009-06-23 2012-09-25 알렉시온 파마슈티칼스, 인코포레이티드 보체 단백질에 결합하는 이중특이적 항체
CN101875696B (zh) * 2009-11-11 2012-02-08 中国人民解放军军事医学科学院生物工程研究所 一种抗体及其制备方法与应用
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
CN102971342B (zh) 2010-01-28 2016-08-03 Ab生物科学公司 亲和力降低的新抗体和制备所述抗体的方法
AU2011223866B2 (en) * 2010-03-01 2015-05-21 Alexion Pharmaceuticals Inc. Methods and compositions for treating Degos' disease
AU2011225716A1 (en) 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
CA2798120A1 (en) 2010-04-30 2011-11-03 Paul P. Tamburini Antibodies having reduced immunogenicity in a human
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
WO2012088247A2 (en) 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
BR112013029893A2 (pt) 2011-05-21 2017-05-30 Macrogenics Inc molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
JP2014520148A (ja) * 2011-06-20 2014-08-21 セントルイス ユニバーシティ 治療のための神経筋接合部への標的化
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20150299313A1 (en) 2011-10-05 2015-10-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
KR20220136441A (ko) 2012-02-24 2022-10-07 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
RS57118B1 (sr) * 2012-03-16 2018-06-29 Regeneron Pharma Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih
NZ730271A (en) 2012-03-16 2022-09-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
CA2869048C (en) * 2012-03-29 2023-10-17 Novimmune S.A. Anti-tlr4 antibodies and uses thereof
TWI619729B (zh) * 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
DK2857419T3 (da) 2012-05-30 2021-03-29 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyle til eliminering af aggregerede antigener
AU2013302925B2 (en) * 2012-08-13 2018-07-05 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
CN105143261B (zh) * 2013-01-31 2021-04-09 首尔大学校产学协力团 C5抗体以及用于预防和治疗补体-相关的疾病的方法
US9321686B2 (en) 2013-03-15 2016-04-26 Forta Corporation Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete
EP2968985A2 (en) 2013-03-15 2016-01-20 Amgen, Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
CA2920293A1 (en) 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
JP6382641B2 (ja) 2013-09-11 2018-08-29 株式会社東芝 非水電解質電池及び非水電解質電池の製造方法
EP4008726A1 (en) 2014-02-20 2022-06-08 Allergan, Inc. Complement component c5 antibodies
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
JP2016024424A (ja) 2014-07-24 2016-02-08 株式会社リコー 情報処理システム、情報処理装置、情報処理方法、及びプログラム
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
BR112017014067B1 (pt) 2015-02-27 2021-01-12 Chugai Seiyaku Kabushiki Kaisha usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
US20190135903A1 (en) 2015-03-31 2019-05-09 Alexion Pharmaceuticals, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
WO2016178980A1 (en) 2015-05-01 2016-11-10 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
US20180142010A1 (en) 2015-06-26 2018-05-24 Alexion Pharmaceuticals, Inc. Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
IL259256B2 (en) 2015-12-18 2023-02-01 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
US10233252B2 (en) 2015-12-21 2019-03-19 Wisconsin Alumni Research Foundation pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
EP3402816A1 (en) 2016-01-11 2018-11-21 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
MA53248A (fr) 2016-01-25 2022-02-16 Takeda Pharmaceuticals Co Anticorps anti-c5 à commutation ph améliorée
LT3468990T (lt) 2016-06-14 2024-06-25 Regeneron Pharmaceuticals, Inc. Anti-c5 antikūnai ir jų panaudojimas
TWI807666B (zh) 2016-06-17 2023-07-01 日商中外製藥股份有限公司 抗c5抗體及使用方法
WO2018143266A1 (en) 2017-01-31 2018-08-09 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
KR20240151866A (ko) 2017-03-14 2024-10-18 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
MA49886A (fr) 2017-03-16 2020-06-24 Medimmune Ltd Anticorps anti-par2 et leurs utilisations
KR20190138806A (ko) 2017-04-03 2019-12-16 인플라알엑스 게엠베하 C5a 활성 억제제에 의한 염증 질병의 치료
BR112020008182A2 (pt) 2017-10-26 2020-10-27 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
KR20200095485A (ko) 2017-12-04 2020-08-10 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
CA3107618A1 (en) 2018-08-01 2020-02-06 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Also Published As

Publication number Publication date
AU2015365167A1 (en) 2017-06-01
TW202031897A (zh) 2020-09-01
JP2017200489A (ja) 2017-11-09
MX2017007616A (es) 2017-09-18
US10023630B2 (en) 2018-07-17
CN107207607B (zh) 2021-05-04
CL2017001585A1 (es) 2018-12-21
US9765135B2 (en) 2017-09-19
CN113045650A (zh) 2021-06-29
EA201791366A1 (ru) 2018-02-28
CL2021000630A1 (es) 2021-07-30
US20190062413A1 (en) 2019-02-28
HRP20211934T1 (hr) 2022-03-18
EP3981794A1 (en) 2022-04-13
EP3233921A1 (en) 2017-10-25
PH12017501114B1 (en) 2023-12-06
TW201632557A (zh) 2016-09-16
KR102515796B1 (ko) 2023-03-30
LT3233921T (lt) 2021-12-10
MX384138B (es) 2025-03-14
US20160176954A1 (en) 2016-06-23
RS62749B1 (sr) 2022-01-31
WO2016098356A1 (en) 2016-06-23
HUE056489T2 (hu) 2022-02-28
EP3233921B1 (en) 2021-09-29
ZA201703241B (en) 2025-12-17
KR20230044338A (ko) 2023-04-03
TWI617580B (zh) 2018-03-11
BR112017011235A2 (pt) 2018-02-06
US20240052021A1 (en) 2024-02-15
PH12017501114A1 (en) 2017-11-27
SG11201607165YA (en) 2016-09-29
US10385122B2 (en) 2019-08-20
RU2017125758A3 (ru) 2019-10-25
JP6755217B2 (ja) 2020-09-16
AR103162A1 (es) 2017-04-19
US20200031913A1 (en) 2020-01-30
TWI725847B (zh) 2021-04-21
AU2015365167B2 (en) 2021-07-29
CO2017006651A2 (es) 2017-09-29
KR20170092449A (ko) 2017-08-11
SG10201710322VA (en) 2018-02-27
US11597760B2 (en) 2023-03-07
TW201809008A (zh) 2018-03-16
PL3233921T3 (pl) 2022-01-10
ES2899894T3 (es) 2022-03-15
MY183415A (en) 2021-02-18
EP3233921A4 (en) 2018-07-11
SI3233921T1 (sl) 2022-01-31
CR20170251A (es) 2017-07-19
JP6174782B2 (ja) 2017-08-02
RU2746356C2 (ru) 2021-04-12
KR101838645B1 (ko) 2018-03-14
JP2017509312A (ja) 2017-04-06
UA128712C2 (uk) 2024-10-09
KR20180029267A (ko) 2018-03-20
CA2967554A1 (en) 2016-06-23
CN107207607A (zh) 2017-09-26
US20180002415A1 (en) 2018-01-04
PT3233921T (pt) 2021-12-09

Similar Documents

Publication Publication Date Title
RU2017125758A (ru) Антитела к с5 и способы их применения
RU2018125624A (ru) Антитела к с5 и способы их применения
MX387662B (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
JP2018521638A5 (ru)
JP2020500538A5 (ru)
PE20240218A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
RU2013140350A (ru) Антитела против человеческого il33r и их применение
NZ758448A (en) Anti-sortilin antibodies and methods of use thereof
FI2691417T4 (fi) Vasta-aineen Fc-variantteja
JP2015533795A5 (ru)
JP2016512551A5 (ru)
JP2013198490A5 (ru)
WO2016191643A4 (en) Tigit-binding agents and uses thereof
NZ715896A (en) Humanized or chimeric cd3 antibodies
HRP20201503T1 (hr) MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79
RU2016100892A (ru) Антитела против tweakr и их применение
JP2012116856A5 (ru)
JP2017536102A5 (ru)
HRP20120759T1 (hr) Bispecifična veziva specifična između vrsta
RU2016137110A (ru) Антитела к компоненту комплемента с5
RU2014127287A (ru) Антитела, используемые для пассивной вакцинации против гриппа
AR103713A1 (es) Anticuerpos contra tau y sus usos
RU2016137256A (ru) АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
RU2017128882A (ru) Антитела к биотину и способы их применения
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения